This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novartis to acquire The Medicines Company

( November 24, 2019, 23:31 GMT | Official Statement) -- MLex Summary: Basel, Switzerland-based Novartis said it will acquire Parsippany, New Jersey-based The Medicines Company in an all-cash transaction with an equity value of $9.7 billion. The transaction between the pharmaceutical companies is expected to close in the first quarter fo 2020. Novartis is traded on the New York Stock Exchange and The Medicines Company is traded on the Nasdaq.Statement follows below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login